Operative Report: Diode Laser Trabeculoplasty (LTP_

Patient: [Patient Name]

DOB: [MM/DD/YYYY]

Date of Procedure: June 8, 2026

Surgeon: David Malitz, MD

Anesthesia: Topical anesthesia (proparacaine 0.5%)

Indication: To enhance compliance and follow community standards in line with the Light Study with Open-angle glaucoma, inadequately controlled with medical therapy, likely progression of glaucomatous optic neuropathy on current treatment

Diagnosis / Procedure

Preoperative Diagnosis: Primary open-angle glaucoma (or specify secondary open-angle glaucoma)

Postoperative Diagnosis: Same as preoperative

Procedure Performed: Diode laser trabeculoplasty (DLT) of the [right/left/both] eye(s)

Findings

Angle appeared open on gonioscopy with visible trabecular meshwork from 3 to 9 o’clock. No synechiae or neovascularization observed.)

Details of Procedure

After informed consent was confirmed, the patient was positioned upright at the slit lamp in the laser suite. Time out was performed verifying patient identity, procedure, laterality, and consent.
Topical anesthetic (proparacaine 0.5%) was instilled into the operative eye.
A gonioscopy lens (e.g., Latina/Goldmann-style contact lens) was applied with coupling fluid to visualize the angle and trabecular meshwork.
Laser settings: Diode Nidek GYC-1000(532 nm) solid-state ophthalmic laser laser with initial power set at 800 mW, with pulse duration 0.1 ms and spot size 50 µm.
Treatment technique: Applied ____ laser applications to the trabecular meshwork covering 180° — specifically between __ and ___ clock hours. Each application was delivered to produce a visible but not destructive response.
Intraoperative IOP was monitored; no significant spikes occurred. There were intermittent bubbles at application sites. No bleeding or anterior chamber reaction was observed.
Upon completion, the gonioscopy lens was removed and the ocular surface was irrigated. Drops of topical steroid, NSAID, ocular hypotensive and a topical antibiotic were instilled if given. The patient was scheduled for follow up and instructed to use medications and was discharged after exam and when ASC criteria were met.
Patient tolerated the procedure well without complications.

Plan

Patient was instructed to use topical steroid (e.g., prednisolone acetate 1% qid) for 5 days. The patient was advised to continue glaucoma medications unless otherwise instructed. Return precautions given: worsening eye pain, vision loss, increased redness, purulent discharge, or persistent nausea/vomiting. Follow-up: IOP check and slit-lamp exam at postoperative scheduled to assess IOP response.

Signature

David Malitz, MD ____/_____/2026